GEORGIA BOARD OF PHARMACY

Georgia Pharmacy Association 6065 Barfield Road, Suite 100 Sandy Springs, GA 30328 September 14, 2022 9:00 a.m.

The following Board members were present:

Dean Stone, President
Michael Azzolin, Vice-President
Jim Bracewell
Michael Brinson
Young Chang
Cecil Cordle
Chuck Page
Bill Prather

Staff present:

Eric Lacefield, Executive Director Dennis Troughton, Director, GDNA Michael Karnbach, Deputy Director, GDNA Max Changus, Assistant Attorney General Elizabeth Simpson, Assistant Attorney General Clint Joiner, Attorney Brandi Howell, Business Support Analyst I

Visitors:

Stephanie Kirkland, Eldercare Jonathan Marquess, GPhA Melissa Reybold, GPhA Christi Heys, Emory Bob Coleman, GPhA Jamie Woods, Eldercare

Bethany Sherrer, Medical Association of Georgia

Stephen Snow, Apotex

Leigh Carpenter, Hemophilia of Georgia

Beth Jarrett, Walmart

Jason Strow, Encompass Health

Maney Mazloom, Peachtree Therapeutics

Chris Claudius, GPhA

Helen Sloat, Hemophilia of Georgia/Kaiser Permanente

Ryann Miller, GHA

Public Hearing

President Stone called the public hearing to order at 9:00 a.m.

Rule 480-15-.02 Registration of Pharmacy Technicians

President Stone stated that the purpose of the rule amendment is to add continuing education requirements for renewal of pharmacy technician registrations. He further stated that the main feature of this proposed amendment adds a requirement for pharmacy technicians to complete continuing education as a requirement of the renewal of their registration.

President Stone explained that with investigative cases reviewed by the Board pharmacy technicians have been involved in some of the errors made. He continued by stating that the Board felt it was necessary to require additional education for technicians to help them become more knowledgeable. President Stone stated that the Board has discussed increased costs and burden, but the Board feels strongly this proposed amendment helps to protect the citizens of Georgia. He further stated that Mr. Brinson has done a lot of research on this matter and there are free continuing education programs that can offset the costs.

Mr. Brinson commented that in 2019 the Board President at the time, Mr. Prather, assigned him with the task of researching continuing education for pharmacy technicians. He stated that the first proposal was to have all pharmacy technicians obtain ten hours of continuing education per year and 20 hours of continuing education as a requirement for renewal of the registration. He further stated that Ms. Thoman's correspondence does discuss costs; however, Mr. Brinson explained that there are free continuing education programs being offered. Mr. Brinson continued by stating that he believes it is a great idea to require continuing education for pharmacy technicians.

No public comments were received. A written response was received from Nina Thoman, PharmD, Stamps Health Services.

Mr. Prather made a motion to adopt Rule 480-15-.02 Registration of Pharmacy Technicians. Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

Rule 480-28-.10 Loss or Theft of Controlled Substances

President Stone stated that the purpose of the rule amendment is to address the obligation of dispensing practitioners and to better align the requirements of this rule with those of Rule 480-16-.06 and O.C.G.A. § 26-4-112. He further stated that the main feature of this proposed amendment addresses the obligation of dispensing practitioners to notify the Georgia Drugs and Narcotics Agency in the event of loss or theft of controlled substances out of a pharmacy.

No public comments were received. A written response was received from Becca Hallum, Georgia Hospital Association.

Mr. Brinson made a motion to adopt Rule 480-28-.10 Loss or Theft of Controlled Substances. Mr. Prather seconded, and the Board voted unanimously in favor of the motion.

The public hearing concluded at 9:06 a.m.

Open Session

President Stone established that a quorum was present and called the meeting to order at 9:06 a.m.

Approval of Minutes

Mr. Brinson made a motion to approve the Public and Executive Session minutes from the August 17, 2022, meeting. Mr. Page seconded, and the Board voted unanimously in favor of the motion.

Report of Licenses Issued

Mr. Page made a motion to ratify the list of licenses issued. Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

Petitions for Rule Waiver or Variance

Rule Waiver Petition from Harbor Springs Counseling Services, LLC: The Board discussed this request for a waiver of Rule 480-18-.02(5). Mr. Brinson made a motion to deny the petition as the Board determined only a Change in Facility Name application was required and would consider the application submitted as such. Mr. Page seconded, and the Board voted unanimously in favor of the motion.

Rule Variance Petition from Harbor Springs Counseling Services, LLC: The Board discussed this request for a variance of Rule 480-18-.05(2)(d)(5). Mr. Page made a motion to grant the petition. Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

Rule Waiver Petition from Apotex Corporation, PHWH001465: Mr. Stephen Snow, representative on behalf of Apotex Corporation, spoke to the Board regarding the facility's request for a waiver of Rule 480-7-.03(3)(c). Mr. Snow stated that, according to the Board's records, the facility did not submit a formal application when it changed its address in 2015; however, he noted that the facility had been at the same address since 2011. He continued by stating that the facility had been operating at the same address for the past ten years. President Stone commented that there was documentation of an application submission in 2005 and asked if any documentation was submitted to the Board office in 2011. Mr. Snow responded by stating that an application was submitted in 2005. He added that the facility thought it sent an application for a change of address in 2011, but could not find any documentation of such.

President Stone inquired if the website tracked when someone changes the address. Mr. Lacefield responded by stating that the address was changed online in February 2012 and was consistent with the renewal receipt at that time. He added that the facility changed its address online and did not notify the Board office of such. Discussion was held regarding the language on the Board's website notifying facilities if the address is changed, the facility must submit an application to the board office.

Mr. Snow discussed the address on the Board's website being incorrect. He requested the website reflect the correct address. Mr. Changus responded by stating that the facility needs to go through the normal process and submit an application for a change in location to the Board office. Mr. Changus explained that, typically, if someone changes the address without submitting an application to the Board there may be a fine or disciplinary action imposed; however, the Board will consider that after the application is submitted. Mr. Snow responded by stating that the facility was concerned about the Board taking disciplinary action and the facility having to report that disciplinary action to the other 49 state boards. He stated the facility would submit an application, but requested the Board to not impose disciplinary action for the oversight. Mr. Changus responded by stating once the facility submitted the application, it could request the Board not impose discipline. There being no further discussion, Mr. Brinson made a motion to deny the petition. Mr. Page seconded, and the Board voted unanimously in favor of the motion.

Rule Waiver Petition HealthQwest-Stockbridge: The Board discussed this request for a waiver of Rule 480-18-.05(1). Mr. Brinson made a motion to grant the petition. Mr. Page seconded, and the Board voted unanimously in favor of the motion.

Correspondences

Correspondence from John F. King, Insurance and Safety Fire Commissioner: The Board discussed this correspondence regarding the practice of white bagging and the significant concerns of such. President Stone stated that this is a topic the Board has discussed several times and he, personally, is not in favor of the practice of white bagging. He further stated that he was glad the Commissioner was looking into the matter. Mr. Brinson commented that white bagging has caused a lot of problems, especially on the retail and hospital sides. He added that it effects many hospitals. He stated that there is not much the Board could do, but appreciated the Commissioner making this matter a priority.

Correspondence from Julianne Padgett, RPH028423: The Board considered this correspondence requesting the Board apply the 15 hours Ms. Padgett earned from the "Endo 2022" course offered by Endocrine Society held June 11, 2022 – June 14, 2022, towards the continuing education requirement for this biennium. The Board recommended denying the request as the provider and sponsor of the course is not board approved. Additionally, the course is not an American Council on Pharmaceutical Education approved course.

Georgia Drugs and Narcotics Agency – Dennis Troughton

Director Troughton reported that GDNA conducted 451 inspections and received 93 complaints for FY2023.

He reported that prior to the Board's next meeting he hopes to have one of the three agent positions filled. He stated that GDNA's goal was to have all three positions filled by the end of FY2023.

Director Troughton reported that GDNA hopes to have its database setup by the end of FY2023.

Attorney General's Report – Max Changus

No report.

Executive Director's Report – Eric Lacefield

Continuing Education Report: Mr. Brinson made a motion to ratify the below continuing education programs approved since the previous meeting. Mr. Cordle seconded, and the Board voted unanimously in favor of the motion.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code
08/09/2022	0.5	Atrium Health – Navicent	Myth Busting -	2022-0009
			Vancomycin	

October Meeting: Mr. Lacefield reported that the October 12th meeting would be held in person at the Department of Community Health offices in Atlanta. He stated that arrangements would be made for lunch as there is no hot food in the building.

Re-Location of Department of Community Health Offices: Mr. Lacefield reported that the move will occur in December.

Legal Services – Clint Joiner

Correspondence sent on behalf of the American Pharmacist Association, the Council on Radionuclides and Radiopharmaceuticals, Inc., the National Association of Nuclear Pharmacies, and the Society of Nuclear Medicine and Molecular Imaging regarding USP General Chapter 825: Mr. Joiner discussed correspondence received requesting the Board adopt USP General Chapter <825>. Mr. Joiner read the following statement issued by the Board in October 2019:

"The United States Pharmacopeia ("USP") announced on September 23, 2019, that – as required by USP by-laws – it is postponing the official dates of the revised USP chapters <795> and <797> and new chapter <825> while appeals for review of these chapters are resolved. These chapters were previously scheduled to go into effect on December 1, 2019.

Existing USP chapters <795> and <797> will continue to be enforced. The GA Drugs & Narcotics Agency (GDNA) will continue to use the inspection forms and tools to existing USP chapter <795> and <797> requirements. As pharmacists know, under GA Law, 26-4-86, and GA Board of Pharmacy Rule, 480-11-.02, compounding activities must comply with USP-NF standards. This includes chapters <795> and <797>. The revised chapters, as well as the new chapter <825>, will be enforced when they go into effect. USP did not set a new effective date in its announcement.

Since USP has announced that as of December 1, 2019, chapter <800> is to be simply informational and not [compendially] applicable, GDNA will not be inspecting for compliance with chapter <800>, until such time that the revised versions of chapters <795> and <797> are made effective by USP.

Again, USP did not set a new effective date in its announcement. Pharmacies working toward chapter <800> compliance are strongly encouraged to take the time afforded by this delay to finalize those preparations."

Mr. Joiner stated that USP did not set a new effective date in its announcement. There was no action taken or discussion held by the Board.

Miscellaneous

Low THC: President Stone commented that the Board has held previous discussions on this matter, but felt it would be good to have a formal process to get it moving. He stated that, in his personal opinion, he feels pharmacists are the perfect people to work with these patients and ensure patient safety. He further stated that pharmacists have the opportunity to show their value with working with the citizens of Georgia.

President Stone requested Mr. Prather provide the Board with an update. Mr. Prather stated that the Georgia Access to Medical Cannabis Commission is currently working through various company protests over who was selected for production licensure for low THC oil, and hopes to move forward as soon as possible.

President Stone explained that the Board of Pharmacy was supposed to work jointly with the Commission, but that changed when the law was amended. He stated that it was great to have Mr. Prather as a connection to the Commission.

President Stone appointed Mr. Cordle and Mr. Brinson to a committee, with Mr. Cordle as Chair, to work with Mr. Joiner and GDNA to further review and make sure the Board's rules align with the law. Mr. Prather stated that himself and Mr. Greg Reybold worked on a draft rule last year that does not cover dispensing, but covers a pharmacy getting the product. He added that the Board needed to promulgate rules that cover dispensing since this is dealing with a Schedule I narcotic. President Stone agreed and stated that the dispensaries are very different from pharmacies.

Mr. Brinson commented that he felt it was great for pharmacists to have the ability to dispense low THC. He stated that pharmacists need to remember to maintain appropriate documentation and records. He further stated that if an individual is selected for a random drug test and fails, many companies will require that individual be terminated.

Chapter 480-36 Retail Pharmacy Requirements for Remote Prescription Drug Order Processing: Discussion was held by the Board regarding Chapter 480-36 and amendments it previously voted to post specifically to Rule 480-36-.03. Vice-President Azzolin made a motion to delete the following language from Rule 480-36-.03(2):

"If a pharmacy technician or pharmacy intern/extern is assisting the secondary remote entry pharmacist, he/she must be located within the licensed pharmacy. Such Secondary remote entry pharmaciests shall comply with Georgia laws and rules set forth pertaining to ratios and the supervision of pharmacy technicians and pharmacy interns/externs."

Discussion was held by Mr. Prather who inquired if the rule would be submitted to the Governor's office. Mr. Changus responded by stating that once the Board voted to post the changes, it was required to give 30 days' notice of its intended action and then a public hearing would be held. Mr. Prather asked if it was correct that the Board could not move forward with the rule until the Governor approved it. President Stone responded affirmatively. There being no further discussion, Mr. Chang seconded, and the Board voted in favor of the motion, with the exception of Mr. Prather, who abstained from the vote.

Mr. Joiner informed the Board that a revised draft of Chapter 480-36 was available on Sharepoint for review. Vice-President Azzolin made a motion to repost Chapter 480-36 Retail Pharmacy Requirements for Remote Prescription Drug Order Processing as amended. Mr. Chang seconded, and the Board voted in favor of the motion, with the exception of Mr. Prather, who abstained from the vote.

480-36-.01. Definitions

As used in this chapter, the following terms:

- (1) "Board" shall mean the Georgia Board of Pharmacy.
- (2) "Remote prescription drug order processing" shall mean the processing of prescription or patient information from a location other than the location from which the prescription medication is received and dispensed. It shall not include the dispensing of a drug, but may include:
 - (a) Receiving the prescription order from the primary dispensing pharmacy
 - (b) Interpreting, analyzing, or clarifying prescriptions;
 - (c) Entering prescription or patient data into a data processing system;
 - (d) Transferring prescription information;
 - (e) Performing a drug regimen review;
 - (f) Performing a drug allergy review;
 - (g) Performing therapeutic interventions; or
 - (h) Any combination of these order processing functions.
- (3) Primary dispensing pharmacy. A primary dispensing pharmacy shall be defined as the retail pharmacy <u>located in this State</u> from which a prescription is physically received and dispensed to the patient or the patient's caregiver.
- (4) Secondary remote entry pharmac<u>yist</u>. A secondary remote entry pharmac<u>yist</u> shall be defined as the retail pharmacy which a pharmacist licensed in this state and located anywhere in the United States who performs remote prescription drug order processing but does not dispense the medication to the patient or the patient's caregiver. There shall only be one secondary remote entry pharmacy ist to assist the primary dispensing pharmacy with remote prescription drug order processing per prescription.

480-36-.02. Licensing

- (1) <u>Secondary remote entry</u> Ppharmacies<u>ts who</u> which perform remote prescription drug order processing shall be independently licensed as a retail pharmacy by the Board and physically located within the State of Georgia.
- (2) When a secondary remote entry pharmacist performs Remote prescription drug processing from any location other than a retail pharmacy, the pharmacy must be licensed in this State is prohibited.
- (3) <u>Secondary remote entry Ppharmaciests who which perform remote prescription drug order processing shall either have the same owner be employed by or contracted with the primary dispensing pharmacy or be employed by an organization that hasve a written contract describing the scope of services to be provided and the responsibilities and accountabilities of each pharmacy and the contractor. Such contract shall be available for review by the Board or its representative.</u>

480-36-.03. Personnel and Supervision

- (1) The primary dispensing pharmacy shall have a licensed pharmacist on site during business hours and his/her shall duties shall include the verification of the validity of all prescriptions. Such pharmacist shall be responsible for obtaining and recording all information needed. This shall include but not be limited to the following patient information: biographical information, medication history, drug allergies, and other information as required. Pharmacy technicians and pharmacy interns/externs may assist a pharmacist located at the primary dispensing pharmacy with remote prescription drug order processing. Such pharmacies shall comply with Georgia laws and rules set forth pertaining to ratios and the supervision of pharmacy technicians and pharmacy interns/externs.
- (2) The secondary remote entry pharmacy shall have a pharmacist on duty, licensed in this State, who is physically present and personally supervising all pharmacy activities. Remote prescription drug order processing in a retail pharmacy without the direct supervision of a pharmacist is prohibited.
- (32) If the secondary remote entry pharmacist is engaging in the remote services listed in rule 480-36-.01 from a Georgia Board of Pharmacy licensed pharmacy, then Ppharmacy technicians and pharmacy interns/externs may assist a the secondary remote entry pharmacist located at the secondary remote

entry pharmacy with remote prescription drug order processing. If a pharmacy technician or pharmacy intern/extern is assisting the secondary remote entry pharmacist, he/she must be located within the licensed pharmacy. Such Secondary remote entry pharmaciests shall comply with Georgia laws and rules set forth pertaining to ratios and the supervision of pharmacy technicians and pharmacy interns/externs.

(43) The secondary remote entry pharmacist on duty at the secondary remote entry pharmacy shall be responsible for assuring the accuracy of prescriptions for which he/she performed or supervised remote prescription drug order processing. This responsibility shall exclude the compounding, preparation, dispensing, and counseling for prescriptions for which he/she has performed remote prescription drug order processing. The pharmacist shall verify the data entered into the computer system is consistent with the prescription. The pharmacist shall conduct a drug regimen review for each prescription. Any activity requiring the exercise of professional judgment shall be performed by the secondary remote entry pharmacist on duty and shall not be delegated to pharmacy technicians. The secondary remote entry pharmacist on duty at the secondary remote entry pharmacy shall be responsible for verification of all activities performed by pharmacy technicians, or pharmacy interns/externs.

480-36-.04. Policy and Procedures

The primary dispensing pharmacy and the secondary remote entry pharmacy shall have a written policy and procedure that relates to the remote processing at each pharmacy involved in the processing of a prescriptions and such policy shall be available for inspection by the Board or its representative. The policy shall at a minimum include the following:

- (a) The responsibilities of each the primary dispensing pharmacy and secondary remote entry pharmacist;
- (b) A list of the name, address, telephone numbers, and permit/registration/license numbers of all pharmacies and pharmacists involved in remote processing;
- (c) Procedures for protecting the confidentiality and integrity of patient information;
- (d) Procedures for ensuring that pharmacists performing prospective drug reviews have access to appropriate drug information resources;
- (e) Procedures for maintaining required records;
- (f) Procedures for complying with all applicable laws and regulations to include counseling.

480-36-.05. Record Keeping

- (1) The primary dispensing pharmacy and the secondary remote entry pharmac<u>yist</u> shall share a common electronic file or have technology which allows sufficient information necessary to process a non-dispensing function.
- (2) In addition to any other required records, the primary dispensing pharmacy and the secondary remote entry pharmacy shall maintain retrievable records which show, for each prescription remotely processed, each individual processing function and identity of the pharmacist or pharmacy technician who performs a processing function and the pharmacist who checked the processing function.
- (3) The primary dispensing pharmacy and the secondary remote entry pharmacy may maintain records separately at each pharmacy, or in a common electronic file shared by both pharmacies provided the system can produce a record showing each processing task, the identity of the person performing each task, and the location where each task was performed. Prescriptions processed by a secondary pharmacist must be separately identifiable and retrievable upon request by a GDNA agent during inspection.
- (4) These records maintained by the primary dispensing pharmacy and the secondary remote entry pharmacy shall be readily retrievable for at least two years through the primary dispensing pharmacy, and shall be available for inspection by the Board or its representative.
- (5) The record keeping required by this rule is in addition to the record keeping required under Rule

Chapter 480-10 and any other Board rules and state and federal laws.

Rule 480-36-.06. Patient Counseling

- (1) It shall be the responsibility of the pharmacist on duty at the primary dispensing pharmacy to perform patient counseling of all prescriptions, as required, including those assisted by remote processing.
- (2) The secondary remote entry pharmac<u>yist</u> shall not perform patient counseling on behalf of the primary dispensing pharmacy.

480-36-.07. Notification to Patients

- (1) Prior to utilizing remote prescription drug order processing, the primary dispensing pharmacy shall:
 - (a) Notify patients their prescription drug order may be processed <u>in part</u> by another <u>offsite</u> <u>pharmacist or pharmacy</u>. Such notification may be provided through a one time written consent from the patient or the patient's authorized representative and through use of a sign in the pharmacy which states: "Remote Order Processing Utilized Here." Such sign must be clear and legible with letters at least three (3) inches in size, and the sign shall be free from obstruction and visible to patients at the time the prescription is presented to the pharmacy.
 - (b) Give the name of that pharmacy, or if the pharmacy is part of a network of pharmacies under a common ownership and any of the network pharmacies may process the prescription order, the patient shall be notified of this fact. Such notification may be provided through a one time written consent from the patient or the patient's authorized representative and through use of a sign in the pharmacy which states: "Remote Order Processing Utilized Here." Such sign must be clear and legible with letters at least three (3) inches in size, and the sign shall be free from obstruction and visible to patients at the time the prescription is presented to the pharmacy.
- (2) Prior to utilizing remote prescription drug order processing, written consent from the patient or the patient's authorized representative shall be obtained by the primary dispensing pharmacy when the primary dispensing pharmacy and the secondary remote entry pharmacy do not share the same owner.

Mr. Page made a motion and Mr. Brinson seconded that the formulation and adoption of these rule amendments does not impose excessive regulatory cost on any licensee and any cost to comply with the proposed rule amendments cannot be reduced by a less expensive alternative that fully accomplishes the objectives of the relevant code sections.

In the same motion, the Board also voted that it is not legal or feasible to meet the objectives of the relevant code sections to adopt or implement differing actions for businesses as listed at O.C.G.A § 50-13-4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these rule amendments will impact every licensee in the same manner, and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

Mr. Lacefield commented that a public hearing would likely be scheduled for November.

Prescription Drug Monitoring Program (PDMP): President Stone thanked Mr. Prather for his time serving on the Electronic Data Base Review Advisory Committee. President Stone appointed Mr. Chang and Mr. Bracewell to serve as members of the committee.

President Stone requested GDNA provide an overview of how the committee works. Deputy Director Karnbach responded by stating that the committee meets quarterly and reviews statistical data. He stated that the committee discusses how companies, pharmacies, physicians, etc., utilize the PDMP database.

Maltagon: President Stone reported that Mr. Cordle and Mr. Chang would be attending the Maltagon meeting later in the month on behalf of the Board. Mr. Chang commented that the meeting would be held in New Orleans and is attended by state board representatives and members of the Drug Enforcement Agency.

Quarterly Newsletter: Mr. Page reported that the distribution date for the next quarterly newsletter would be September 30th. He requested the members submit any suggestions to him or Mr. Chang. Mr. Page inquired if there were any comments from members of the public regarding the newsletter. Mr. Marquess commented that GPhA received a lot of positive feedback.

Mr. Brinson commented that it would be helpful to let other pharmacists know how busy GDNA is and how many inspections it conducts. Director Troughton responded by stating that he would write something up for inclusion in the newsletter.

Mr. Page commented that if there was anyone not on the distribution list who wished to be added, please let the Board know. He stated that the Board wants to make sure it reaches the majority of pharmacists in the state. President Stone stated that himself and Mr. Lacefield continue to talk about how to get a better email service. He continued by stating that there is a lot happening behind the scenes with GDNA, board staff, and the Attorney General's office that the public is not aware of that include other tasks and working with another board.

Prescription Alerts: President Stone discussed a statewide initiative to promote awareness to South Carolina health care professionals and law enforcement in an effort to stop illegal prescription activities. He stated that he hopes this may be an option for Georgia in the future.

Renewals: Mr. Lacefield commented that renewals for pharmacists should be live around October 1st.

Board Member Listing: President Stone inquired about a list he found on GDNA's website that contains board member names. He stated that the list stops around 2016/2017 and requested it be updated with current information. Director Troughton responded by stating that he maintains a list, but does not post the information on GDNA's website, but would do so if the Board requested. President Stone requested Director Troughton email the information to the members.

GPhA: Mr. Jonathan Marquess welcomed everyone to GPhA. He noted that Mr. Bob Coleman, Chief Executive Offer, as well as Ms. Melissa Reybold, Vice-President of Public Policy, were also present. He stated that if there was anyone interested in a tour, to please let Mr. Coleman know. President Stone thanked GPhA for hosting the meeting.

Mr. Prather made a motion and Mr. Brinson seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h) and § 43-1-2(h) to deliberate and to receive information on applications, investigative reports, and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Michael Azzolin, Jim Bracewell, Michael Brinson, Young Chang, Cecil Cordle, Chuck Page, Bill Prather, and Dean Stone.

Executive Session

<u>Georgia Drugs and Narcotics Agency – Dennis Troughton</u> No report.

Cognizant's Report - Michael Azzolin

• GDNA Case # A34145

- GDNA Case # B34360
- GDNA Case # B34311
- GDNA Case # B34317
- GDNA Case # B34330
- GDNA Case # A34402
- GDNA Case # B34267
- GDNA Case # A34391
- GDNA Case # A34383
- GDNA Case # A34373
- GDNA Case # A34355
- GDNA Case # A34351
- GDNA Case # B34339
- GDNA Case # A34056
- GDNA Case # A34345
- GDNA Case # A34294
- GDNA Case # B34347
- GDNA Case # B34271
- GDNA Case # B34334
- GDNA Case # B34327
- GDNA Case # B34307
- GDNA Case # B34326
- GDNA Case # B34335
- GDNA Case # B34310

Attorney General's Report - Max Changus

Mr. Changus discussed staffing matters.

Mr. Changus presented the following consent order for acceptance:

• M.C.W.D.

Ms. Simpson discussed the following case:

• GDNA Case # A33920

Executive Director's Report – Eric Lacefield

Mr. Lacefield discussed correspondence regarding complaint matters.

Legal Services

• U.E.

Applications

- T.L.D.
- T.L.M.
- H.D.J.
- E.G.L.
- B.K.D.
- G.B.C.
- J.W.R.
- M.J.E.
- M.F.

- M.K.A.
- S.M.P.

Correspondences/Requests

- O.M.
- O.M.
- O.M.H.L.
- O.M.H.L.
- O.M.D.I.
- S.R.P.
- S.R.P.
- T.R.I.
- E.P.
- M.M.T.
- M.M.T.
- P.P.A.P.
- R.P.
- M.P.I.
- P.P.A.P.
- A.P.
- A.P.
- A.P.
- A.P.
- A.P.
- A.P.
- R.A.S.
- A.S.D.
- P.S.H.
- J.J.S.
- M.N.R.
- L.J.L.
- N.D.S.
- E.H.R.H.C.
- M.W.D.
- R.H.C.M.

No votes were taken in Executive Session. President Stone declared the meeting back in Open Session.

Open Session

Mr. Brinson made a motion for the Board to take the following actions:

Georgia Drugs and Narcotics Agency - Dennis Troughton

No report.

Cognizant's Report – Michael Azzolin ■ GDNA Case # A34145 Ref

•	GDNA Case # B34360	Misfill Policy #1
•	GDNA Case # B34311	Close with letter of concern
•	GDNA Case # B34317	Misfill Policy #1 to PIC/Refer to the Department of Law for pharmacy
•	GDNA Case # B34330	Close with letter of concern
•	GDNA Case # A34402	Refer to the Department of Law

Refer to the Department of Law

GDNA Case # B34267
 GDNA Case # A34391
 Refer to the Department of Law

• GDNA Case # A34383 Letter of concern to PIC/Refer to the Department of Law for pharmacy

• GDNA Case # A34373 Refer to the Department of Law

• GDNA Case # A34355 Refer to the Department of Law once application is complete

GDNA Case # A34351
 GDNA Case # B34339
 GDNA Case # A34056
 GDNA Case # A34345
 GDNA Case # A34345
 GDNA Case # A34294
 Refer to the Department of Law Refer to the Department of Law Refer to the Department of Law

GDNA Case # A34294
GDNA Case # B34347
GDNA Case # B34271
GDNA Case # B34334
GDNA Case # B34327
GDNA Case # B34327
GDNA Case # B34307
Close with no action Close with no action Close with no action

GDNA Case # B34307
 GDNA Case # B34326
 GDNA Case # B34335
 Close with no action Close with no action

• GDNA Case # B34310 Close with no action

Attorney General's Report - Max Changus

Mr. Changus discussed staffing matters.

Mr. Changus presented the following consent order for acceptance:

• M.C.W.D. Private Consent Order accepted

Ms. Simpson discussed the following case:

• GDNA Case # A33920 Deny counterproposal

Executive Director's Report – Eric Lacefield

Mr. Lacefield discussed correspondence regarding complaint matters. The Board viewed this correspondence for informational purposes only.

Legal Services

• U.E. Request regarding payment plan for fine Accepted payment plan

Applications

T.L.D. Pharmacy Technician Approved for registration T.L.M. Pharmacy Technician Approved for registration H.D.J. Pharmacist Intern Approved application Pharmacist Exam Applicant Approved application E.G.L. Pharmacist Reciprocity Applicant B.K.D. Approved application Pharmacist Reciprocity Applicant Approved application G.B.C. Approved application Pharmacist Reciprocity Applicant J.W.R. Temporary Pharmacist Applicant Denied application M.J.E. Pharmacist Certification of DTM Approved application M.F. Approved pending receipt of Pharmacist Certification of DTM M.K.A. additional information

• S.M.P. Pharmacist Certification of DTM Approved application

Correspondences/Requests

NI . CD: 11	
Notice of Discipline	No action
±	No action
Notice of Discipline	No action
Notice of Discipline	No action
Notice of Discipline	No action
Request to terminate probation	Approved request effective 10/13/2022
Request to terminate probation	Approved request
Request regarding supervising pharmacist	Approved request
Request for 4 th attempt to retake MPJE	Approved request
	Notice of Discipline

	• M.N.R.	Request for 4 th attempt to retake NAPLEX	Approved request
	L.J.L.	Request for 5 th attempt to retake NAPLEX	Approved request
	• N.D.S.	Request for 4 th attempt to retake NAPLEX	11 1
		and request for extension of intern license	(extension approved thru
			03/31/2023)
	• E.H.R.H.C.	Remote order entry	Approved request
	• M.W.D.	Request regarding reinstatement	Board directed staff to respond
			by stating it would reconsider the
			request once a completed
			application for reinstatement was
			received.
,	• R.H.C.M.	Remote order entry	Approved request

Mr. Page seconded, and the Board voted unanimously in favor of the motion.

There being no further business to discuss, the meeting was adjourned at 1:52 p.m.

The next scheduled meeting of the Georgia Board of Pharmacy will be held on Wednesday, October 12, at 9:00 a.m., at the Department of Community Health's office located at 2 Peachtree Street, N.W., 5th Floor, Atlanta, GA 30303.

Minutes recorded by Brandi Howell, Business Support Analyst I Minutes edited by Eric Lacefield, Executive Director